非小细胞肺癌新辅助放疗联合免疫治疗——研究进展分析
摘要
新辅助放疗和单纯免疫治疗相比，新辅助放疗与免疫治疗的联合使用在非小细胞肺癌中显示出更好的临床结局和病
理完全缓解率。然而，目前暂无具体的治疗方案形成治疗标准。本文总结了新辅助放疗联合免疫治疗在非小细胞肺
癌中应用的一些临床研究，来对放疗的具体剂量与分割、放疗与免疫治疗的时序以及新辅助治疗完成后的手术间隔
等问题展开讨论。对放疗联合免疫治疗的具体作用机制及治疗的疗效生物标志物进行了总结。希望通过对新辅助放
疗联合免疫治疗非小细胞肺癌的具体过程、机制、疗效检测的进一步认识来为临床治疗方案的选择和未来临床研究
设计提供参考。
关键词
全文:
PDF参考
[1]Siegel, R. L., Miller, K. D., Mbbs, N. S. W. & Dvm,
A. J. Cancer statistics, 2023. (2023).
[2]涂海燕，孙月丽，柯娥娥 & 吴一龙.2023年肺癌
临床研究新进展.循证医学23，348–359（2023）.
[3]邵雅楠，张悦，乔欣怡，吴云娇 & 王萌.免疫检
查点抑制剂新辅助治疗Ⅰ-Ⅲ期非小细胞肺癌的临床研
究进展.现代肿瘤医学32，3354–3359（2024）.
[4]Vanpouille-Box, C. et al. DNA exonuclease Trex1
regulates radiotherapy-induced tumour immunogenicity.
Nat. Commun. 8, 15618 (2017).
[5]Teng, F. et al. Optimum fractionation of radiation to
combine PD‐1 blockade. MedComm 4, e271 (2023).
[6]Palma, D. A. et al. Measuring the Integration of
Stereotactic Ablative Radiotherapy Plus Surgery for EarlyStage Non–Small Cell Lung Cancer: A Phase 2 Clinical
Trial. JAMA Oncol. 5, 681 (2019).
[7]Lee, J. et al. Phase Ib study of neoadjuvant concurrent
chemoradiation plus durvalumab followed by surgery and
adjuvant durvalumab for resectable stage III NSCLC. J. Clin.
Oncol. 41, 8556–8556 (2023).[8]Li, J. et al. Neoadjuvant low-dose radiotherapy plus
durvalumab and chemotherapy for potentially resectable stage
III NSCLC: A phase Ib dose-escalation study. Radiother.
Oncol. 196, 110316 (2024).
[9]Spigel, D. R. et al. Five-Year Survival
Outcomes From the PACIFIC Trial: Durvalumab After
Chemoradiotherapy in Stage III Non–Small-Cell Lung
Cancer. J. Clin. Oncol. 40, 1301–1311 (2022).
[10]Zhao, Z.-R. et al. Stereotactic body radiation
therapy with sequential immunochemotherapy as neoadjuvant
therapy in resectable non-small cell lung cancer (SACTION-
01 study).
[11]Theelen, W. S. M. E. et al. Effect of Pembrolizumab
After Stereotactic Body Radiotherapy vs Pembrolizumab
Alone on Tumor Response in Patients With Advanced
Non–Small Cell Lung Cancer: Results of the PEMBRORT Phase 2 Randomized Clinical Trial. JAMA Oncol. 5,
1276–1282 (2019).
[12]Liu, H. et al. A phase II randomized trial evaluating
consolidative nivolumab in locally advanced non-small cell
lung cancer post neoadjuvant chemotherapy plus nivolumab
and concurrent chemoradiotherapy (GASTO-1091). J. Clin.
Oncol. 42, 8008–8008 (2024).
[13]Dickhoff, C. et al. Ipilimumab plus nivolumab and
chemoradiotherapy followed by surgery in patients with
resectable and borderline resectable T3-4N0–1 non-small
cell lung cancer: the INCREASE trial. BMC Cancer 20, 764
(2020).
[14]Altorki, N. K. et al. Neoadjuvant durvalumab with
or without stereotactic body radiotherapy in patients with
early-stage non-small-cell lung cancer: a single-centre,
randomised phase 2 trial. Lancet Oncol. 22, 824–835 (2021).
[15]Portella, L. & Scala, S. Ionizing radiation effects on
the tumor microenvironment. Semin. Oncol. 46, 254–260
(2019).
[16]Zhou, X. et al. Safety and Tolerability of Low-Dose
Radiation and Stereotactic Body Radiotherapy þ Sintilimab
for Treatment-Naïve Stage IV PD-L1þ Non–Small Cell
Lung Cancer Patients. Clin. CANCER Res.
[17]Yang, H., Jin, T., Li, M., Xue, J. & Lu, B.
Synergistic effect of immunotherapy and radiotherapy in nonsmall cell lung cancer: current clinical trials and prospective
challenges. Precis. Clin. Med. 2, 57–70 (2019).
[18]Ishizuka, J. J. et al. Loss of ADAR1 in tumours
overcomes resistance to immune checkpoint blockade. Nature
565, 43–48 (2019).
[19]van Gulijk, M., Dammeijer, F., Aerts, J. G. J. V. &
Vroman, H. Combination Strategies to Optimize Efficacy of
Dendritic Cell-Based Immunotherapy. Front. Immunol. 9,
2759 (2018).
[20]Provencio, M. et al. Neoadjuvant chemotherapy
and nivolumab in resectable non-small-cell lung cancer
(NADIM): an open-label, multicentre, single-arm, phase 2
trial. Lancet Oncol. 21, 1413–1422 (2020).
[21]任胜祥 & 邱天羽.肺癌精准治疗的发展与展
望.肿瘤防治研究50，442–451（2023）.
[22]Chaft, J. E. et al. Neoadjuvant atezolizumab for
resectable non-small cell lung cancer: an open-label, singlearm phase II trial. Nat. Med. 28, 2155–2161 (2022).
[23]Theelen, W. S. M. E. et al. Effect of Pembrolizumab
After Stereotactic Body Radiotherapy vs Pembrolizumab
Alone on Tumor Response in Patients With Advanced
Non–Small Cell Lung Cancer: Results of the PEMBRORT Phase 2 Randomized Clinical Trial. JAMA Oncol. 5,
1276 (2019).
[24]徐世豪 & 钱俊.非小细胞肺癌免疫治疗的研究进
展.转化医学杂志13，284–287（2024）.
[25]Vanpouille-Box, C. et al. DNA exonuclease Trex1
regulates radiotherapy-induced tumour immunogenicity.
Nat. Commun. 8, 15618 (2017).
[26]Rizvi, N. A. et al. Mutational landscape determines
sensitivity to PD-1 blockade in non–small cell lung cancer.
Science 348, 124–128 (2015).
[27]Krieg, C. et al. High-dimensional single-cell
analysis predicts response to anti-PD-1 immunotherapy. Nat.
Med. 24, 144–153 (2018).
[28]董懂，黄意恒，张亚杰 & 李鹤成.《中华医学会
肺癌临床诊疗指南（2023版）》解读.中国胸心血管外科
临床杂志30，1533–1538（2023）.
[29]Wang, Y. et al. Dynamic bTMB combined with
residual ctDNA improves survival prediction in locally
advanced NSCLC patients with chemoradiotherapy and
consolidation immunotherapy. J. Natl. Cancer Cent. 4, 177–
187 (2024).
Refbacks
- 当前没有refback。
